Does Cediranib Prevent Bowel Perforation in Platinum-resistant Ovarian Cancer

Ovarian cancer can often grow and cause obstructions in the bowel. These obstructions usually cannot be removed with surgery and can be fatal. This trial is testing whether a drug called cediranib can be used safely together with paclitaxel chemotherapy to treat ovarian cancer in women at risk of bowel obstructions. All participants will receive the cediranib/paclitaxel combination, and if the cancer worsens the participant will stop receiving paclitaxel and may receive an additional drug, olaparib, together with cediranib.

NCT Number	NCT07648745
Lead Sponsor	Prof Gordon Jayson Collaborators: AstraZeneca, Cardiff University
Conditions	Bowel Obstruction, Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Cancer
Enrollment	30 participants
Start Date	2018-05-14
Primary Completion	2025-01-14 (estimated)
Study Completion	2025-01-14 (estimated)
Updated on ClinicalTrials.gov	2026-06-15